NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“Company” or “NurExone”) has recently unveiled laboratory tests of
its secondary two proprietary sequences, representing a significant
advancement in the treatment of spinal cord injuries. The
biopharmaceutical company is using its biologically-guided exosome
therapy ExoTherapy platform to expand its portfolio of products
that will address spinal cord injuries and regeneration of neurons
in other CNS indications.
In the latest development, NurExone has
developed two selective small inhibiting RNA sequences (siRNA) that
target and inhibit proteins within the Peri-Neural Network (PNN)
complex (Fig. 1A). The breakthrough sequences, detailed in a patent
application held by the Company, are built upon a scientifically
validated strategy for enhanced neuronal regeneration via
inhibition of the PNN complex. The Company believes that its
innovative approach, using the Company’s ExoTherapy platform to
deliver these RNA sequences, will overcome limitations of previous
methods. This marks a potential for two new products in the
Company’s portfolio. The promise of the Company’s new sequences is
evident in Figures 1B-1C, where PNN is notably reduced
post-treatment.
ExoPTEN, the Company’s first product under
development, employs a distinct mechanism of action while sharing
the same exosome-based drug delivery system. ExoPTEN has progressed
to rat models, displaying regenerative properties and restoration
of motor function, with human trials anticipated in the foreseeable
future.
Dr. Nisim Perets, inventor of the new approach,
comments, “Inhibiting the proteins responsible for constructing the
PNN scaffolding may restore the inherent neuro-regenerative
potential humans are born with. This could be a game-changer in the
treatment of spinal cord injury.”
Dr. Lior Shaltiel, CEO of NurExone, adds, “Our
scientific advancements and developments with the ExoTherapy
platform are progressing rapidly, and the diversity of molecules in
our arsenal will broaden our capacity to address neurological
illnesses.”
Figure 1: (A) Illustration of the extracellular Perineural
network (PNN), highlighted in green. (B) Immunohistology of one
protein in the PNN in differentiated neuronal culture demonstrate
that the new treatment on human neuronal culture successfully
degraded the PNN.(C) Quantification of one PNN building block
protein that was successfully inhibited by the new
treatment.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated in animal studies at the Technion,
Israel Institute of Technology. NurExone is translating the
treatment to humans, and the company holds an exclusive worldwide
license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please
visit www.nurexone.com or follow NurExone
on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and
DirectorPhone: +972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation -
CanadaPhone: +1 905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation -
GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect
management’s current beliefs and are based on information currently
available to management as at the date hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our ability to retain key personnel, our ability to
continue investing in research and development, our ability to
secure available funding and to continue as a going concern, the
general business and economic conditions of the industries and
countries in which we operate, our ability to execute on our
business strategy, that there will be certain amount of demand for
the Company’s potential product, inflation will remain stable, and
that the results of our studies reflect results that can be
extrapolated.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d1febbe6-921b-431a-b844-a814be12e06b
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024